echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Determining the speech subtypes of patients with DeNovo Parkinson's disease: response to long-term treatment with levodopa

    Neurology: Determining the speech subtypes of patients with DeNovo Parkinson's disease: response to long-term treatment with levodopa

    • Last Update: 2021-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Several clinical signs of Parkinson's disease (PD), such as predominant tremor, postural instability and gait difficulty, rapid eye movement sleep behavior disorder, cognitive impairment, and autonomic dysfunction, are thought to constitute Different disease phenotypes have different prognosis and treatment response
    .


    Hypodynamic dysarthria, which is found in up to 90% of patients during the progression of the disease, is characterized by single pitch, reduced pressure, monotony, imprecise consonants, inappropriate silence, harsh wheezing, and abnormal voice timing


    Hypodynamic dysarthria, which is found in up to 90% of patients during the progression of the disease, is characterized by single pitch, reduced pressure, monotony, imprecise consonants, inappropriate silence, harsh wheezing, and abnormal voice timing


    Recently, researchers have determined the speech subtypes of patients with Parkinson's disease after treatment and checked their response to long-term dopaminergic treatment


    The researchers recorded the voice data of 111 Parkinson's disease patients, 83 of whom completed a 12-month follow-up (69 Parkinson's disease patients received stable dopaminergic treatment, 14 untreated Parkinson's disease Patient)
    .


    Unsupervised k-means cluster analysis was performed on the eight characteristic parameters of motor dysarthria examined by quantitative acoustic analysis


    • Three different speech subtypes were detected with similar prevalence, symptom duration, and exercise severity: "prosody subtype", "speech subtype" and "speech subtype"
      .
    • In addition to the common monophonic and monochromatic subtypes, the speech subtypes with difficulty in pronunciation and the pronunciation subtypes with inaccurate pronunciation of consonants are more serious than the prosodic subtypes
      .
    • Clinically, the prosody subtype is characterized by more women and younger age, while the pronunciation subtype is more common in men, older age, heavier axial gait symptoms, and poor cognitive ability
      .


      The speech subtype represents the intermediate state of age clinically, most of which are men, and cognitive ability is preserved


      Different language disorder phenotypes of patients with new-onset Parkinson's disease reflect different underlying mechanisms and can predict the response of language disorder to levodopa treatment


      https://n.
      neurology.
      org/content/early/2021/10/04/WNL.
      0000000000012878.
      long Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.